Tandem Labs
Omaha, NE, and Salt Lake City, UT, October 26, 2006 (PR Newswire) - Qualia Clinical Services, a leading provider of Phase I-IV clinical research, and Tandem Labs, a premier bioanalytical and immuoanaltyical testing laboratory, announced their strategic alliance today. This partnership creates a compelling value proposition for the pharmaceutical, biotechnology, and generic industries by providing access to streamlined drug development services with an unprecedented emphasis on quality and efficiency.
The combined force of Qualia and Tandem offers clients access to the complete suite of services related to clinical research. As a result of the alliance, clients can expect to:
"The need for accurate data delivered in a timely fashion is critical to our clients. Through our alliance with Tandem Labs, Qualia now has access to one of the leading bioanalytical laboratories. Their core values are aligned with ours - both companies are client focused and have a passion for quality. The foundation of combined industry experience is quite impressive," said Sohail Khattak, MD, FRCP(C), president and CEO of Qualia. "Additionally, from a geographic standpoint, we are perfectly equipped to serve our clients' needs for a completely integrated approach. Qualia's main clinic is located in the middle of the United States while Tandem has facilities on the East and West Coasts. These are truly exciting times not only for our company, but also for the clients we serve."
"This alliance gives us the unique opportunity to partner with another CRO that provides exceptional customer care combined with scientific expertise," said Denis Lin, Ph.D., president and CEO of Tandem Labs. "It is a true partnership: Qualia's strong clinical research foundation combined with Tandem's scientific knowledge, low-risk approach, and technologies."
Serving the pharmaceutical, biotechnology, and generic industries, Qualia offers extensive expertise in early phase clinical research (Phase I-IIa) and late-phase clinical trials (Phase IIb-IV), clinical pharmacology, bioequivalence, PK/PD analysis, data management, and statistical services. Its access to a large base of normal healthy participants and special populations ensures rapid study initiation and on-time completion. With facilities in Canada, United States, and Europe, Qualia is redefining the clinical research industry in terms of innovation, flexibility, and customer focus. Detailed information about the company is available at www.qualiaclinical.com or by calling 1-866-629-7100.
Tandem Labs is a leading bioanalytical contract research organization (CRO) specializing in advanced mass spectrometry and immunoanalytical support as well as pharmacokinetics and pharmacodynamics (PK/PD) for the pharmaceutical and biopharmaceutical industries in the United States and internationally. Bioanalytical service offerings include rapid method development of LC/MS/MS and GC/MS/MS assays to support clinical and pre-clinical studies adhering to Good Laboratory Practices (GLP) as well as discovery work specializing in rapid development, abbreviated validations, and high-throughput analysis of non-GLP samples. Immunoanalytical services include method development, validation, and sample analysis for novel and esoteric biomarkers as well as the analysis of biotherapeutics and antibodies. PK and PD services use DMDiscoverySM and MarkerScanSM, proprietary informatics used for metabolite profiling, identification, and quantification; biomarker discovery and screening; protein-binding assays; and discovery bioanalytical support services. With this comprehensive suite of services, Tandem's mission is to help clients reduce their overall time in bringing new medicines to market using a disciplined, low-risk approach.
Certain statements in this press release constitute "forward-looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the Company's management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.
Search